News & Updates

Show Multimedia Only

COVID-19 circuit-breaker leads to unhealthy diets among Singapore’s frontliners

05 Oct 2022 by

During the circuit-breaker, healthcare workers (HCWs) in Singapore often keep unhealthy dietary patterns and see a decrease in their self-regulatory (SR) eating behaviours, according to a recent study.

05 Oct 2022

Inflammation ups risk of chemo-induced decline in frailty status in older women with breast cancer

05 Oct 2022 by

Robust older women with early breast cancer who have high prechemotherapy levels of both interleukin-6 (IL-6) and C-reactive protein (CRP) are >3 times more likely to experience chemotherapy-induced decline in frailty status than their counterparts with low levels of these inflammatory markers, a prospective study has shown.

05 Oct 2022

Maternal cardiomyopathy linked to adverse perinatal outcomes

05 Oct 2022

Pregnancies complicated by maternal cardiomyopathy are at risk of adverse perinatal outcomes, according to a systematic review and meta-analysis.

05 Oct 2022

Quick progression to castration resistance tied to survival in nonmetastatic CRPC

05 Oct 2022

In men with nonmetastatic castration-resistant prostate cancer (M0CRPC), the prostate-specific antigen (PSA) doubling time and the time to castration resistance (TTCRPC) predict cancer-specific survival (CSS), a recent study has found.

05 Oct 2022

Lower pre-dialysis creatinine ups death risk in acute kidney injury

05 Oct 2022

Among patients with acute kidney injury requiring dialysis therapy (AKI-D), lower levels of pre-dialysis creatinine may be a useful predictor of mortality risk, a recent study has found.

05 Oct 2022

Niraparib maintenance boosts PFS in advanced ovarian cancer

05 Oct 2022 by

Maintenance therapy with the PARP* inhibitor niraparib led to a sustained and durable progression-free survival (PFS), regardless of biomarker status, in patients with primary advanced ovarian cancer who responded to platinum-based chemotherapy, an updated analysis of the phase III PRIMA/ENGOT-OV26/GOG-3012 trial has shown.

05 Oct 2022

Tirzepatide confers renal protection in patients with T2D

05 Oct 2022 by

Once-weekly injection of tirzepatide, a dual GIP and GLP-1 receptor antagonist, slowed eGFR* decline and reduced UACR** in patients with type 2 diabetes (T2D) who are at high risk of cardiovascular (CV) disease compared with once-daily insulin glargine (iGlar), according to a prespecified post hoc analysis of the SURPASS-4*** trial presented at EASD 2022.

05 Oct 2022

Deucravacitinib bestows benefits in Asian patients with plaque psoriasis

04 Oct 2022 by

The benefit of deucravacitinib in moderate to severe plaque psoriasis was demonstrated in a population of Asian patients, according to results of the phase III POETYK PSO-3 trial.